Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RASTEM is an autologous adipose-derived mesenchymal stem cell (ADMSC) therapy being developed by EHL Bio for the treatment of moderate to severe rheumatoid arthritis. The therapy involves isolating mesenchymal stem cells from a patient's own adipose tissue, expanding them in vitro, and administering them back to the patient via intravenous injection. RASTEM functions through immunomodulation and tissue repair, leveraging the multi-differentiation potential of adult stem cells to suppress the inflammatory immune response and promote the regeneration of damaged joint tissues. As of early 2024, the candidate has completed non-clinical studies and is in the preclinical stage, preparing for clinical trial entry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RASTEM.